Positive Results for Neovasc's Reducer System Treatment for Refractory Angina Published in Cardiology Journal
- Tiara Clinical Updates presented at TVT and ISMICS Medical Conferences -
VANCOUVER, June 20, 2016 - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN - News) (TSX:NVC.TO -News) reported today that the positive results of a single center, retrospective study using the Reducer product were published in the June 14, 2016 issue of The Netherlands Heart Journal in an article titled "Safety and efficacy of a device to narrow the coronary sinus for the treatment of refractory angina: A single center real world experience". The paper documented the results from 23 consecutive patients who were implanted with the Reducer in order to treat their severe refractory angina.
The published results demonstrated that in all 23 patients the Reducer device was successfully implanted in a day hospital setting without any adverse events. After a median follow-up of 9 months (range 8 – 14 months) it was found that 17 of 23 patients showed at least one class improvement in their Canadian Cardiovascular Society (CCS) angina score: 8 patients (34.8%) improved by 1 CCS class, 7 (30.4%) by 2 CCS classes and 2 (8.7%) by 3 CCS classes.
- Published: 20 June 2016
- Written by Editor
- Hits: 77